BH-30236

N/A

Report date: 2024/07/17 20:00:53
NME

Base Information

Drug NameBH-30236
Drug Alias NameBH-30236
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionClk dual-specificity kinase inhibitors
TargetsDual specificity protein kinase CLK
Therapy Area/IndicationsMyelodysplastic SyndromesLung NeoplasmsHematologic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlossomHill Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBlossomHill Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLung NeoplasmsHematologic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A